DK2995626T3 - BIFUNCTIONAL FUSION PROTEINS TO INHIBIT ANGIOGENESIS IN TUMOR ENVIRONMENTS AND ACTIVATE ADAPTIVE IMMUNE RESPONSE, AND THE GENES AND APPLICATIONS THEREOF - Google Patents

BIFUNCTIONAL FUSION PROTEINS TO INHIBIT ANGIOGENESIS IN TUMOR ENVIRONMENTS AND ACTIVATE ADAPTIVE IMMUNE RESPONSE, AND THE GENES AND APPLICATIONS THEREOF Download PDF

Info

Publication number
DK2995626T3
DK2995626T3 DK14795356.6T DK14795356T DK2995626T3 DK 2995626 T3 DK2995626 T3 DK 2995626T3 DK 14795356 T DK14795356 T DK 14795356T DK 2995626 T3 DK2995626 T3 DK 2995626T3
Authority
DK
Denmark
Prior art keywords
ala
leu
gly
ser
val
Prior art date
Application number
DK14795356.6T
Other languages
Danish (da)
English (en)
Inventor
Shuzhen Wang
Yijun Chen
Dongyang He
Nan Liu
Chao Ma
Zhenyue Gao
Original Assignee
Univ China Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201310162738.3A external-priority patent/CN103214584B/zh
Priority claimed from CN201310163407.1A external-priority patent/CN103232543B/zh
Application filed by Univ China Pharma filed Critical Univ China Pharma
Application granted granted Critical
Publication of DK2995626T3 publication Critical patent/DK2995626T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK14795356.6T 2013-05-06 2014-05-05 BIFUNCTIONAL FUSION PROTEINS TO INHIBIT ANGIOGENESIS IN TUMOR ENVIRONMENTS AND ACTIVATE ADAPTIVE IMMUNE RESPONSE, AND THE GENES AND APPLICATIONS THEREOF DK2995626T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310162738.3A CN103214584B (zh) 2013-05-06 2013-05-06 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
CN201310163407.1A CN103232543B (zh) 2013-05-06 2013-05-06 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用
PCT/CN2014/076768 WO2014180288A1 (zh) 2013-05-06 2014-05-05 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用

Publications (1)

Publication Number Publication Date
DK2995626T3 true DK2995626T3 (en) 2018-10-29

Family

ID=51866722

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14795356.6T DK2995626T3 (en) 2013-05-06 2014-05-05 BIFUNCTIONAL FUSION PROTEINS TO INHIBIT ANGIOGENESIS IN TUMOR ENVIRONMENTS AND ACTIVATE ADAPTIVE IMMUNE RESPONSE, AND THE GENES AND APPLICATIONS THEREOF

Country Status (6)

Country Link
US (1) US10875903B2 (enExample)
EP (1) EP2995626B1 (enExample)
JP (1) JP2016520053A (enExample)
DK (1) DK2995626T3 (enExample)
ES (1) ES2686968T3 (enExample)
WO (1) WO2014180288A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
BR112019007267A2 (pt) * 2016-12-20 2019-07-09 Hoffmann La Roche anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
RU2769769C2 (ru) 2017-01-05 2022-04-05 Кахр Медикал Лтд. СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
LT3565579T (lt) 2017-01-05 2023-09-11 Kahr Medical Ltd. Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
KR20210044221A (ko) 2018-07-11 2021-04-22 카 메디컬 리미티드 Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
CN116640226B (zh) * 2022-04-02 2024-04-26 广东东阳光药业股份有限公司 一种抑制宿主抗外源免疫细胞hvg反应的嵌合受体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1705248A1 (en) * 1997-10-01 2006-09-27 G.D. Searle LLC. Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment
EP1086129A1 (en) * 1998-06-17 2001-03-28 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and methods of use thereof
EP1501861A4 (en) * 2002-05-06 2007-06-20 Univ Texas TARGETED BINDING PROTEINS FOR THE ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC REAGENTS
CA2575441A1 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers
WO2009086132A2 (en) * 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
CN101265482A (zh) * 2008-04-25 2008-09-17 罗以勤 重组肿瘤抑素-肿瘤坏死因子分泌型真核表达载体及其制备方法和用途
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
EP3670536A3 (en) 2011-04-01 2020-10-07 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
AU2012296588B2 (en) * 2011-08-17 2017-07-27 The Regents Of The University Of Colorado, A Body Corporate Transferrin-tumstatin fusion protein and methods for producing and using the same
CN103232543B (zh) * 2013-05-06 2014-12-03 中国药科大学 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用
CN103214584B (zh) * 2013-05-06 2014-07-09 中国药科大学 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用

Also Published As

Publication number Publication date
JP2016520053A (ja) 2016-07-11
US20200062818A1 (en) 2020-02-27
ES2686968T3 (es) 2018-10-23
EP2995626A1 (en) 2016-03-16
EP2995626A4 (en) 2016-11-09
EP2995626B1 (en) 2018-07-11
US10875903B2 (en) 2020-12-29
WO2014180288A1 (zh) 2014-11-13

Similar Documents

Publication Publication Date Title
DK2995626T3 (en) BIFUNCTIONAL FUSION PROTEINS TO INHIBIT ANGIOGENESIS IN TUMOR ENVIRONMENTS AND ACTIVATE ADAPTIVE IMMUNE RESPONSE, AND THE GENES AND APPLICATIONS THEREOF
EP0510691B1 (en) DNA coding for human cell surface antigen
CN105142677B (zh) 嵌合抗原受体及其使用方法
JP4411330B2 (ja) 腫瘍壊死因子関連リガンド
DK2646464T3 (en) Anti Cancer Fusion Protein
CA2422033A1 (en) Method for treating inflammation
CN112543767A (zh) Pd1-4-1bbl变体融合蛋白及其使用方法
WO2013013639A1 (zh) 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
JP2002300890A (ja) 組換えヤドリギレクチン(rML)
KR20090122426A (ko) 종양 거부 항원 ny-eso-1 및 lage-1을 포함하는 융합 단백질
CN109265565A (zh) 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用
RO120919B1 (ro) Proteină hematopoietină, moleculă de acid nucleiccare o codifică, compoziţie farmaceutică şi utilizarea proteinei
CN101698852B (zh) 具有cd137l功能的蛋白或多肽及其基因和应用
WO2005121340A1 (ja) 新規ガレクチン8改変体タンパク質及びその用途
CN113105554B (zh) 一种抗肿瘤融合蛋白及其制法和应用
WO1998053072A1 (en) The production of human granulocyte colony-stimulating factor
CN103232543B (zh) 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用
CN109422814B (zh) 一种抗La/SSB嵌合体抗原修饰的NK细胞、其制备方法及其应用
JPH08333394A (ja) ラット肥満遺伝子、その遺伝子産物およびその製造法
CN106674353B (zh) 一种新的天花粉融合蛋白及其应用
KR101651330B1 (ko) 세포투과성이 우수한 tat-a20 융합단백질의 제조방법 및 이의 용도
CN103214584B (zh) 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
JP2004518410A5 (enExample)
JP2000516465A (ja) トロンボポイエチン・ポリペプチドの製造のための発現ベクター、細胞、及び方法
CN101670114B (zh) 生存素与热休克蛋白的复合物及其制备方法和应用